iShares US Pharmaceuticals ETF
125 hedge funds and large institutions have $143M invested in iShares US Pharmaceuticals ETF in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 11 closing their positions.
387% more capital inflows, than outflows
Capital inflows: $41.9M | Capital outflows: $8.61M
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
5.97% more ownership
Funds ownership: 27.25% → 33.22% (+6%)
2% more funds holding
Funds holding: 122 → 125 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EE
EWG Elevate
Roseville,
California
|
+$6.32M |
| 2 |
Morgan Stanley
New York
|
+$5.2M |
| 3 |
Goldman Sachs
New York
|
+$4.05M |
| 4 |
Atria Wealth Solutions
New York
|
+$3.61M |
| 5 |
Merit Financial Group
Alpharetta,
Georgia
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.87M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$1.16M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$1.14M |
| 4 |
Southern Capital Advisors
Jackson,
Tennessee
|
-$1.04M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$730K |
IHE Hedge Fund Activity: Q2 2022 in Review
125 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2022, worth a combined $143M — up 14% from $125M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new IHE positions and 11 closed out — a net gain of 4 holders — while 34 added to existing stakes and 30 trimmed.
The largest buyer was EWG Elevate, opening a new position worth an estimated $6.32M. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.87M sold.
- 125 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2022, up from 122 in Q1 2022.
- Funds reported $143M of iShares US Pharmaceuticals ETF stock for Q2 2022, up 14% quarter-over-quarter.
- 15 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2022 and 11 closed out, a net change of +4 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2022 was EWG Elevate, an estimated $6.32M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2022 was Citadel Advisors, an estimated $1.87M sold.
Based on aggregated 13F filings for Q2 2022.